SCHEDULE: J&J Reduces Stake in Rapport Therapeutics to 4.9%

Johnson & Johnson and its subsidiary JJDC have reduced their beneficial ownership in Rapport Therapeutics, Inc. to 4.9% of common stock.

Summary

• Johnson & Johnson (J&J) and its wholly-owned subsidiary, Johnson & Johnson Innovation JJDC, Inc. (JJDC), have filed an Amendment No. 1 to their Schedule 13G for Rapport Therapeutics, Inc.
• The filing indicates a beneficial ownership of 1,784,517 shares of Rapport Therapeutics' Common Stock by the reporting persons.
• This ownership represents 4.9% of the class of securities, based on 36,497,920 shares outstanding as of August 4, 2025.
• The event requiring this filing, which signifies a change in ownership, occurred on September 30, 2025.
• J&J and JJDC previously filed a Schedule 13G on October 18, 2024, indicating a prior ownership stake above 5%.
• JJDC directly owns the securities, while J&J is deemed to indirectly own them as the parent company.

Sentiment

Score: 3

Explanation: The reduction in a significant institutional investor's stake, particularly from a strategic player like Johnson & Johnson, is generally viewed negatively by the market. While not a complete divestment, dropping below the 5% threshold suggests a decreased level of commitment or a strategic re-evaluation, which can impact investor confidence.

Negatives

• Johnson & Johnson and its subsidiary JJDC have reduced their beneficial ownership in Rapport Therapeutics, Inc. from above 5% to 4.9%.
• This reduction suggests a decreased conviction or a strategic shift by a significant institutional investor, which can be perceived negatively by the market.

Risks

• A reduction in ownership by a major strategic investor like Johnson & Johnson could signal a loss of confidence or a shift in strategic priorities regarding Rapport Therapeutics.
• Such a move might be interpreted negatively by the market, potentially impacting investor sentiment and the company's stock price.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Rapport Therapeutics' future operations or financial performance.

Industry Context

This filing indicates a reduction in a significant strategic investment by a major pharmaceutical and healthcare conglomerate, Johnson & Johnson, in a biotechnology company, Rapport Therapeutics. While the specific reasons for the reduction are not disclosed, such moves by large corporate venture arms like JJDC can reflect portfolio rebalancing, a change in strategic focus, or a reassessment of the investee company's prospects within the competitive biotechnology landscape. It could also be a natural part of an investment lifecycle, such as exiting a position after an IPO or a certain development milestone.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on stock price due to a major investor reducing its stake.
• Management: May face questions regarding the company's strategic direction or performance that led to the investor's decision.
• Employees: No direct impact mentioned, but significant shifts in major investor confidence can indirectly affect company stability and morale.

Key Dates

Recommendation

The reduction of Johnson & Johnson's stake in Rapport Therapeutics to below 5% signals a potential loss of confidence or a strategic divestment by a significant institutional investor. This move, especially from a strategic partner like J&J's venture arm, is typically interpreted negatively by the market and could lead to downward pressure on the stock price. Investors might consider selling to mitigate potential losses or re-evaluate their position given this development.

Keywords

Rapport Therapeutics, Johnson & Johnson, JJDC, SEC Filing, Schedule 13G, Beneficial Ownership, Stock Ownership, Institutional Investor, Biotechnology, Pharmaceuticals